

S1 Table: Characteristics at first-line antiretroviral treatment initiation of adult patients from two South African cohorts, 2010–2013: enhanced-data sample and routine-data group

	Khayelitsha		Themba Lethu	
	Enhanced-data sample	Routine-data group	Enhanced-data sample	Routine-data group
n	2367	7263	1470	4296
Men, n (%)	844 (36)	2 567 (35)	582 (40)	1 676 (39)
Mean age in years (SD)	35 (±9)	36 (±9)	39 (±9)	39 (±9)
Median CD4 count in cells/μL (IQR)	180 (99 to 249)	178 (97 to 251)	149 (76 to 223)	143 (65 to 219)
Pregnant, n (percentage of women)	107 (7)	317 (7)	17 (2)	43 (2)
Current tuberculosis, n (%) ¹	593 (25)	1 807 (25)	177 (12)	533 (12)
First line antiretrovirals, n (%):				
Abacavir	0	2 (0.03)	10 (1)	29 (1)
Zidovudine	115 (5)	348 (5)	37 (3)	111 (3)
Stavudine	192 (8)	572 (8)	284 (19)	809 (19)
Tenofovir	2 070 (87)	6 341 (87)	1 139 (77)	3 348 (78)
Efavirenz	2 005 (85)	6 172 (85)	1 350 (92)	3 935 (92)
Nevirapine	341 (14)	1 038 (14)	81 (6)	235 (5)
Lopinavir (ritonavir-boosted)	21 (1)	53 (1)	39 (3)	124 (3)
Atazanavir	0	0	0	2 (0.05)

1. Tuberculosis status unknown in 70 patients. IQR: interquartile range); SD: standard deviation